Therapeutic | Istiratumab |
Target 1 | IGF1R |
Heavy Chain 1 | EVQLLQSGGGLVQPGGSLRLSCAASGFMFSRYPMHWVRQAPGKGLEWVGSISGSGGATPYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDFYQILTGNAFDYWGQGTTVTVSS |
Light Chain 1 | DIQMTQSPSSLSASLGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYAKSTLQSGVPSRFSGSGSGTDFTLTISSLQPEDSATYYCQQYWTFPLTFGGGTKVEIK |
100% seqID Fv 1 Structure | None |
99% seqID Fv 1 Structure | None |
95-98% seqID Fv 1 Structure | None |
Target 2 | ERBB3 |
Heavy Chain 2 | QVQLVQSGGGLVQPGGSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVAGISWDSGSTGYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDLGAYQWVEGFDYWGQGTLVTVSS |
Light Chain 2 | SYELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSTSGNSASLTITGAQAEDEADYYCNSRDSPGNQWVFGGGTKVTVL |
100% seqID Fv 2 Structure | None |
99% seqID Fv 2 Structure | None |
95-98% seqID Fv 2 Structure | None |
Follow these links to our prediction tools:
Format | Bispecific Mixed mAb and scFv |
Isotype | G1;na |
Highest Clinical Trial (Jan '20) | Phase-II |
Estimated Status (Jan '20) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2017 |
INN Year Recommended | 2018 |
Companies Involved | Adimab, Merrimack Pharmaceuticals |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Ovarian cancer, Pancreatic cancer, Solid tumours |
Notes |